Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Tretinoin (ATRA) + Retifanlimab

Stage Phase 2

Sponsor University of Pennsylvania (Stephen Bagley)

Modality small molecule plus antibody

Class retinoid plus PD-1 antibody

Target PD-1 / PD-L1 (TEC-0014)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/api/v2/studies?query.cond=glioma&query.term=IDH

ClinicalTrials.gov API v2: IDH-mutant glioma interventional records plus 34 individual records, retrieved 11.07.2026 (registry fields as entered by sponsors)

Brief source I16

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05345002

A Phase 2 Trial of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT05345002

Registry NCT05345002

Phase Phase 2

Status Recruiting

Enrollment 55

Start 2022-11-16

Primary completion 2027-06-01

Study completion 2028-06-01

Catalyst Primary completion. 06.01.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.